AprilBio Raises 155 Billion KRW via Convertible Preference Shares, Diluting Existing Shareholders by Approximately 15%

AprilBio has decided to issue 3,608,595 convertible preference shares at 42,953 KRW per share via a third-party allotment, raising approximately 155 billion KRW for operating expenses, primarily R&D. The initial conversion price is 42,953 KRW, convertible into common shares at a 1:1 ratio.
The dilution ratio is approximately 15.4% based on current outstanding shares, posing significant risk to existing shareholder value. The conversion price can be adjusted downwards to a floor of 30,068 KRW, potentially increasing dilution if the stock price declines. However, the issue price includes a premium over the current market price and a 1-year lock-up period mitigates immediate selling pressure.
The counterparties are TKGChemicals, a large industrial company, and IMM Startup Venture Fund No. 2, an institutional fund, both considered credible. The proceeds will be fully allocated to research and development.
[AI Summary]AprilBio's 155 billion KRW convertible preference share issuance dilutes existing shareholders by over 15%. While funds are earmarked for R&D, the large capital raise and potential further dilution from conversion price adjustments create near-term uncertainty. Shareholder value may be pressured.